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Effect of four monthly oral vitamin D3 (cholecalciferol)
supplementation on fractures and mortality in men and
women living in the community: randomised double blind
controlled trial
Daksha P Trivedi, Richard Doll, Kay Tee Khaw
Abstract
Objective To determine the effect of four monthly
vitamin D supplementation on the rate of fractures in
men and women aged 65 years and over living in the
community.
Design Randomised double blind controlled trial of
100 000 IU oral vitamin D3 (cholecalciferol)
supplementation or matching placebo every four
months over five years.
Setting and participants 2686 people (2037 men and
649 women) aged 65›85 years living in the general
community, recruited from the British doctors register
and a general practice register in Suffolk.
Main outcome measures Fracture incidence and total
mortality by cause.
Results After five years 268 men and women had
incident fractures, of whom 147 had fractures in
common osteoporotic sites (hip, wrist or forearm, or
vertebrae). Relative risks in the vitamin D group
compared with the placebo group were 0.78 (95%
confidence interval 0.61 to 0.99, P=0.04) for any first
fracture and 0.67 (0.48 to 0.93, P=0.02) for first hip,
wrist or forearm, or vertebral fracture. 471
participants died. The relative risk for total mortality
in the vitamin D group compared with the placebo
group was 0.88 (0.74 to 1.06, P=0.18). Findings were
consistent in men and women and in doctors and the
general practice population.
Conclusion Four monthly supplementation with
100 000 IU oral vitamin D may prevent fractures
without adverse effects in men and women living in
the general community.
Introduction
Osteoporotic fractures are projected to increase expo›
nentially worldwide.1 Most fracture prevention trials
have focused on clinically defined groups such as
people with osteoporosis or previous fractures and
have mainly been conducted in women.2–7 Safe,
effective, feasible, and cost effective primary prevention
measures are needed in older men and women, in
whom most osteoporotic fractures occur. We report
results from a randomised double blind trial of four
monthly supplementation with oral vitamin D3 on frac›
tures and mortality in 2686 men and women aged
65›85 years living in the community.
Methods
Study population
This trial was a pilot to assess the feasibility of a
community trial (not subsequently conducted owing to
lack of funding) in 20 000 men and women. We
recruited men and women aged 65›85 from the British
doctors study register at the Clinical Trials Studies
Unit, Oxford,8 and the age›sex register of a general
practice in Ipswich, Suffolk. Cambridge local ethics
committee approved the study.
Recruitment and randomisation
We recruited participants by using a mailed letter and
information sheet. We excluded people who were
already taking vitamin D supplements and people with
conditions that were contraindications to vitamin D
supplementation—for example, a history of renal
stones, sarcoidosis, or malignancy.
We sent invitations to 11 120 people (9582 from
the British doctors study and 1538 from general prac›
tice), and 3504 (31.5%) of them (2907 from British
doctors study and 597 from general practice) initially
agreed to participate. From June 1996 to March 1997
we randomised 2686 (77.5%) people who were eligible
and gave informed consent, after stratification by age
and sex, to receive either treatment with vitamin D or a
placebo. Participants and investigators were blinded to
the treatment until the study ended, when Ipswich
Pharmacy revealed the coding.
Study design
We conducted the study by post. Participants
completed an initial questionnaire. We assessed preva›
lence of disease with the question “Do you have the
following conditions?” followed by a checklist. We used
a modified food frequency questionnaire at four years
to estimate dietary calcium intake.
Intervention
We sent one capsule containing 100 000 IU vitamin D3
(cholecalciferol) or matching placebo by post every
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four months for five years (15 doses in total). We asked
participants to take the capsule immediately on
receipt, complete a form indicating that they had done
so, and return the form by Freepost.
The dose had previously been shown to be safe, to
raise blood 25›hydroxyvitamin D concentrations to
physiological levels achievable by lifestyle means, and
to have a measurable impact on concentrations of
parathyroid hormone over several weeks.9 The
expected differences in blood concentrations of
25›hydroxyvitamin D and parathyroid hormone are
associated with differences in bone density and fracture
risk.10 11
Participants continued any usual drug treatment
and any new drugs that were advised during routine
care. If they were advised to start vitamin D
supplements of more than 200 IU daily they discontin›
ued the trial intervention but continued to be followed
for endpoints.
Endpoint ascertainment
On receiving the capsule, participants filled in a check›
list of events (fracture or major illness) and returned
the form by Freepost. All participants were flagged at
the Office for National Statistics for mortality and
followed until 31 March 2002. A nosologist blind to the
intervention coded death certificates by using ICD›9
(international classification of diseases, 9th revision).
We ascertained incidences of fracture, cardiovascular
disease, and cancer by using events identified from
questionnaires or death certification by cause.
Serum 25›hydroxyvitamin D, parathyroid hormone,
and heel sonometry
After four years we invited 235 participants from gen›
eral practice who had taken at least 10 capsules to a
clinic for measurement of serum vitamin D and
parathyroid hormone concentrations. The visit took
place in September and October, about three weeks
after a dose. We assessed heel bone sonometry with
CUBA equipment (McCue Ultrasonics, Winchester).
Statistical analyses
We included all participants randomised to active vita›
min D or placebo in the analyses, according to
intention to treat. We compared relative risks for
incidence of fracture, mortality by cause, and incidence
of cardiovascular disease and cancer for active vitamin
D versus placebo by using crude rates and then, after
adjustment for age, with the Cox regression method,12
by using SPSS software, version 10.0.
Results
Characteristics of participants
Table 1 shows baseline descriptive data. Mean calcium
intake at four years was 742 mg/day and did not differ
by treatment allocation.
Incidence of fracture
Table 2 shows five year fracture rates. Participants in
the vitamin D treatment group had a 22% lower rate
for first fracture at any site and a 33% lower rate for a
fracture occurring in the hip, wrist or forearm, or
Table 1 Characteristics of 2037 men and 649 women aged 65›85 years at baseline in 1996, according to allocation to treatment with
vitamin D or placebo. Values are numbers (percentages) unless stated otherwise
Baseline variables
All Men Women
Vitamin D
(n=1345)
Placebo
(n=1341)
Vitamin D
(n=1019)
Placebo
(n=1018)
Vitamin D
(n=326)
Placebo
(n=323)
Mean (SD) age at randomisation (years) 74.8 (4.6) 74.7 (4.6) 75.2 (4.6) 75.0 (4.6) 73.7 (4.5) 73.6 (4.6)
Mean (SD) body mass index (kg/m2) 24.3 (3.4) 24.4 (3.0) 24.3 (3.3) 24.4 (2.7) 24.4 (3.8) 24.3 (3.8)
History of heart disease* 223 (16.6) 208 (15.5) 189 (18.5) 181 (17.8) 34 (10.4) 27 (8.4)
History of stroke 51 (3.8) 57 (4.3) 42 (4.1) 48 (4.7) 9 (2.8) 9 (2.8)
History of cardiovascular disease† 394 (29.3) 367 (27.4) 329 (32.3) 312 (30.6) 65 (19.9) 55 (17.0)
History of cancer‡ 82 (6.1) 79 (5.9) 67 (6.6) 69 (6.8) 15 (4.6) 10 (3.1)
Current smokers 59 (4.4) 53 (4.0) 39 (3.8) 29 (2.8) 20 (6.1) 24 (7.4)
Current use of steroids 60 (4.5) 70 (5.2) 42 (4.1) 53 (5.2) 18 (5.5) 17 (5.3)
Current use of hormone replacement therapy NA NA NA NA 21 (6.4) 21 (6.5)
Alcohol intake§: (n=1295) (n=1279) (n=972) (n=968) (n=323) (n=311)
Never 132 (10.2) 115 (9.0) 77 (7.9) 64 (6.6) 55 (17.0) 51 (16.4)
Occasional 197 (15.2) 205 (16.0) 102 (10.5) 115 (11.9) 95 (29.4) 90 (28.9)
Regular 966 (74.6) 959 (75.0) 793 (81.6) 789 (81.5) 173 (53.6) 170 (54.7)
Physical activity§: (n=1288) (n=1276) (n=969) (n=963) (n=319) (n=313)
Active or moderately active 1119 (86.9) 1133 (88.8) 840 (86.7) 852 (88.5) 279 (87.5) 281 (89.8)
NA=not applicable.
*Self reported angina, myocardial infarction, or ischaemic heart disease.
†Ischaemic heart disease, stroke, or other cardiovascular disease.
‡Includes self reported skin cancers (including melanoma), which comprise about 80% of prevalent cancer; people reporting cancer after randomisation but before
taking the first capsule are reported as prevalent cancer.
§Excludes missing data.
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Fig 1 Cumulative probability of any first fracture according to
treatment with vitamin D (n=1345) or placebo (n=1341), based on
Cox regression; difference between two groups, P=0.04
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vertebrae. The differences were consistent when strati›
fied by sex or by doctor versus general practice popu›
lation. We observed differences one year into the study
(fig 1).
Other health events
Table 3 shows cumulative mortality to March 2002.
The vitamin D group had slightly but not significantly
lower mortality from all causes, cardiovascular disease,
and cancer than the placebo group. Figure 2 shows the
cumulative probability of survival in the vitamin D
group compared with the placebo group over five
years. Table 4 shows the incidence of major health
events. These did not differ significantly between the
treatment groups.
Physiological variables and compliance
Table 5 shows mean serum concentrations of vitamin
D and parathyroid hormone and heel bone ultrasound
attenuation in the subgroup. Mean vitamin D concen›
trations were 40% higher in the active treatment group
than in the placebo group. Mean parathyroid
concentrations were 6% lower, but this difference was
not significant. Heel ultrasound measures did not differ
by treatment.
Compliance did not differ between doctors and the
general practice population or between the treatment
groups; 76% (2050/2686) of participants had at least
80% compliance (12/15 doses). Compliance for the
final dose was 66% (1784/2686); excluding partici›
pants who had died, we estimated compliance to be
80% (1784/2215). A total of 631 (23.5%) participants,
including those who died, did not complete the full five
years to March 2002—22.8% (307) in the vitamin D
group and 24.2% (324) in the placebo group (P=0.41).
No significant difference existed between the two
groups in the number known to be alive but who with›
drew (that is, discontinued questionnaire follow up)
from the study: 5.7% (77) in the placebo group and
6.2% (83) in the active group (P=0.64).
Discussion
Among men and women aged 65›85 living in the
general population, those allocated to supplementa›
tion with vitamin D had lower rates of fracture at any
site or at any major osteoporotic site (hip, wrist or fore›
arm, or vertebrae). We ascertained the incidence of
fracture through self report by questionnaire. This may
have led to ascertainment errors, but random errors
would underestimate associations. In this randomised
double blinded design, biased ascertainment between
the treatment groups is unlikely. Most of the
participants were doctors, which increases the likeli›
Table 2 Incidence of fractures based on self report or mortality certification 1996›2002
and age adjusted relative risks (Cox regression), according to treatment allocation at
randomisation (intention to treat) in 2686 men and women aged 65›85 years. Values
are numbers (percentages) unless stated otherwise
Fractures Vitamin D Placebo
Age adjusted relative
risk (95% CI) P value*
All (n=1345) (n=1341)
Any site 119 (8.8) 149 (11.1) 0.78 (0.61 to 0.99) 0.04
Hip, wrist or forearm, or vertebrae 60 (4.5) 87 (6.5) 0.67 (0.48 to 0.93) 0.02
Hip or wrist or forearm 43 (3.2) 62 (4.6) 0.67 (0.46 to 0.99) 0.04
Hip 21 (1.6) 24 (1.8) 0.85 (0.47 to 1.53) 0.59
Vertebrae 18 (1.3) 28 (2.1) 0.63 (0.35 to 1.14) 0.12
Men (n=1019) (n=1018)
Any site 77 (7.6) 91 (8.9) 0.83 (0.61 to 1.13) 0.24
Hip, wrist or forearm, or vertebrae 36 (3.5) 50 (4.9) 0.70 (0.46 to 1.08) 0.11
Hip or wrist or forearm 22 (2.2) 31 (3.0) 0.70 (0.40 to 1.20) 0.19
Hip 11 (1.1) 14 (1.4) 0.76 (0.35 to 1.67) 0.49
Vertebrae 14 (1.4) 22 (2.2) 0.62 (0.32 to 1.22) 0.17
Women (n=326) (n=323)
Any site 42 (12.9) 58 (18.0) 0.68 (0.46 to 1.01) 0.05
Hip, wrist or forearm, or vertebrae 24 (7.4) 37 (11.5) 0.61 (0.37 to 1.02) 0.06
Hip or wrist or forearm 21 (6.4) 31 (96) 0.64 (0.37 to 1.11) 0.11
Hip 10 (3.1) 10 (3.1) 0.98 (0.41 to 2.36) 0.97
Vertebrae 4 (1.2) 6 (1.9) 0.65 (0.18 to 2.30) 0.50
*P value (two sided) refers to difference between treatment groups.
Table 3 Mortality from all causes, cardiovascular disease, and cancer by death
certification 1996›2002 and age adjusted relative risks (Cox regression), according to
treatment allocation at randomisation (intention to treat) in 2686 men and women aged
65›85 years. Values are numbers (percentages) unless stated otherwise
Cause of death* Vitamin D Placebo
Age adjusted relative
risk (95% CI) P value†
All (n=1345) (n=1341)
All causes 224 (16.7) 247 (18.4) 0.88 (0.74 to 1.06) 0.18
Cardiovascular disease 101 (7.5) 117 (8.7) 0.84 (0.65 to 1.10) 0.20
Ischaemic heart disease 42 (3.1) 49 (3.7) 0.84 (0.56 to 1.27) 0.41
Cerebrovascular disease 28 (2.1) 26 (1.9) 1.04 (0.61 to 1.77) 0.89
Cancer 63 (4.7) 72 (5.4) 0.86 (0.61 to 1.20) 0.37
Colon 7 (0.5) 11 (0.8) 0.62 (0.24 to 1.60) 0.33
Respiratory 10 (0.7) 11 (0.8) 0.89 (0.38 to 2.09) 0.78
Men (n=1019) (n=1018)
All causes 199 (19.5) 220 (21.2) 0.88 (0.73 to 1.07) 0.19
Cardiovascular disease 90 (8.8) 106 (10.4) 0.83 (0.62 to 1.10) 0.19
Ischaemic heart disease 38 (3.7) 45 (4.4) 0.83 (0.54 to 1.28) 0.40
Cerebrovascular disease 24 (2.4) 25 (2.5) 0.92 (0.52 to 1.61) 0.77
Cancer 56 (5.5) 59 (5.8) 0.93 (0.64 to 1.34) 0.69
Colon 7 (0.7) 7 (0.7) 0.97 (0.34 to 2.78) 0.96
Respiratory 10 (1.0) 9 (0.9) 1.08 (0.44 to 2.65) 0.87
Women (n=326) (n=323)
All causes 25 (7.7) 27 (8.4) 0.91 (0.53 to 1.56) 0.73
Cardiovascular disease 11 (3.4) 11 (3.4) 0.99 (0.43 to 2.30) 0.99
Ischaemic heart disease 4 (1.2) 4 (1.2) 0.99 (0.25 to 3.96) 0.99
Cerebrovascular disease 4 (1.2) 1 (0.3) 3.98 (0.44 to 35.64) 0.22
Cancer 7 (2.1) 13 (4.0) 0.53 (0.21 to 1.33) 0.18
Colon 0 4 (1.2) NA 0.04
Respiratory 0 2 (0.6) NA 0.16
Breast 0 0 NA NA
NA=not applicable.
*Cardiovascular disease=ICD›9 codes 390.0›459.9; ischaemic heart disease=410.0›414.0; cerebrovascular
disease=430.0›438.0; cancer=140.0›239.9; colon cancer=153.0›154.8; respiratory cancer=160.0›165.9;
breast cancer=174.0›175.0; each as underlying cause.
†P value refers to difference between treatment groups.
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Fig 2 Cumulative survival according to treatment with vitamin D
(n=1345) or placebo (n=1341), based on Cox regression; no
significant difference between groups
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hood of accurate ascertainment of events. Fracture
rates did not differ significantly between doctors and
the general practice population, indicating that people
in the general community report fracture accurately,
an assumption supported by several studies.13 14
Comparisons with previous studies
Several studies report that daily supplementation with
vitamin D and calcium reduces fractures.2 3 Chapuy
reported that daily supplementation with vitamin D
800 IU and calcium reduced hip fractures by 30% over
three years in 3270 elderly women.2 Whether calcium
alone, vitamin D alone, or the combination was
responsible for these effects is not clear. In our study
the effect size of isolated vitamin D supplementation—
about 20% reduction in total fractures and 30% reduc›
tion in fractures at major osteoporotic sites—is
comparable to that reported by Chapuy for combined
daily vitamin D and calcium.2
Previous studies of isolated vitamin D supplemen›
tation have been inconclusive.15–17 The lack of
significant reduction in fractures in these studies could
be explained by a lack of power due to a lower dose of
supplement, shorter duration, or lower number of
events as well as ineffectiveness of vitamin D. Lips
found no protective effect of vitamin D 400 IU daily in
1578 participants.16 This dose may have been too low
to achieve a clinical effect. In our study the four
monthly 100 000 IU dose averages a daily equivalent
similar to the 800 IU vitamin D used in the trials by
Chapuy and Dawson Hughes.2 3 Heikinheimo, using
annual injections of 150 000›300 000 IU in 899
participants, reported a reduction in fractures of the
upper limb but not the lower limb.17 This study was not
properly randomised or blinded, and a single annual
dose may not provide adequate concentrations in the
blood over a whole year.
Vitamin D may protect against fractures through
concentrations of parathyroid hormone. Low concen›
trations of vitamin D are associated with increased
concentrations of parathyroid hormone, increased
bone resorption, and lower bone mass.9–11 The 40%
higher mean concentrations of vitamin D seen in the
active treatment group in our trial were still not high
in absolute terms. Parathyroid hormone concentra›
tions were only slightly and not significantly lower.
This suggests that 100 000 IU vitamin D four monthly
may not have lowered parathyroid hormone concen›
trations adequately, and a more frequent dose might
be considered in future trials.
We found no significant effects of vitamin D on
total mortality or incidence of cancer or cardiovas›
cular disease, as suggested by observational studies.18 19
However, the fact that the relative risks were in a
favourable direction in the active treatment group is
reassuring.
Table 4 Incidence of cardiovascular disease, cancer, and other health events 1996›2002
and age adjusted relative risks, according to treatment allocation at randomisation
(intention to treat) in 2686 men and women aged 65›85 years. Values are numbers
(percentages) unless stated otherwise
Health event Vitamin D Placebo
Age adjusted relative
risk (95% CI) P value*
All (n=1345) (n=1341)
Cardiovascular disease† 477 (35.5) 503 (37.5) 0.90 (0.77 to 1.06) 0.22
Ischaemic heart disease 224 (16.7) 233 (17.4) 0.94 (0.77 to 1.15) 0.57
Cerebrovascular disease 105 (7.8) 101 (7.5) 1.02 (0.77 to 1.36) 0.87
Cancer† (any) 188 (14.0) 173 (12.9) 1.09 (0.86 to 1.36) 0.47
Cancer† (excluding skin) 144 (10.8) 130 (9.6) 1.11 (0.86 to 1.42) 0.43
Colon cancer 28 (2.1) 27 (2.0) 1.02 (0.60 to 1.74) 0.94
Respiratory cancer 17 (1.3) 15 (1.1) 1.12 (0.56 to 2.25) 0.75
Self reported falls‡ (n=1027) (n=1011)
254 (24.7) 261 (25.8) 0.93 (0.76 to 1.14) 0.50
Self reported health‡: (n=1017) (n=1002)
Excellent or good 788 (77.5) 760 (75.8) 1.13 (0.91 to 1.39) 0.27
Men (n=1019) (n=1018)
Cardiovascular disease† 392 (38.5) 412 (40.5) 0.91 (0.76 to 1.09) 0.30
Ischaemic heart disease 191 (18.7) 193 (19.0) 0.98 (0.78 to 1.22) 0.86
Cerebrovascular disease 86 (8.4) 85 (8.3) 0.99 (0.72 to 1.36) 0.96
Cancer† (any) 163 (16.0) 147 (14.4) 1.11 (0.87 to 1.42) 0.39
Cancer† (excluding skin) 129 (12.7) 111 (10.9) 1.17 (0.89 to 1.54) 0.26
Colon cancer 25 (2.5) 21 (2.1) 1.18 (0.65 to 2.12) 0.59
Respiratory cancer 17 (1.7) 13 (1.3) 1.29 (0.62 to 2.68) 0.49
Self reported falls‡ (n=757) (n=756)
154 (20.3) 169 (22.4) 0.87 (0.68 to 1.12) 0.27
Self reported health‡: (n=749) (n=750)
Excellent or good 577 (77.0) 582 (77.6) 1.00 (0.78 to 1.28) 0.99
Women (n=326) (n=323)
Cardiovascular disease† 85 (26.1) 91 (28.2) 0.89 (0.63 to 1.27) 0.52
Ischaemic heart disease 33 (10.1) 40 (12.4) 0.79 (0.48 to 1.29) 0.35
Cerebrovascular disease 19 (5.8) 16 (5.0) 1.19 (0.60 to 2.37) 0.62
Cancer† (any) 25 (7.2) 26 (8.0) 0.95 (0.54 to 1.68) 0.85
Cancer† (excluding skin) 15 (4.6) 19 (5.9) 0.77 (0.39 to 1.55) 0.47
Colon cancer 3 (0.9) 6 (1.9) 0.49 (0.12 to 1.98) 0.32
Respiratory cancer 0 2 (0.6) NA 0.16
Breast cancer 4 (1.2) 4 (1.2) 0.99 (0.25 to 3.99) 0.99
Self reported falls‡ (n=270) (n=255)
100 (37.0) 92 (36.1) 1.03 (0.72 to 1.48) 0.86
Self reported health‡: (n=268) (n=252)
Excellent or good 211 (78.7) 178 (70.6) 1.57 (1.05 to 2.35) 0.03
NA=not applicable.
*P value refers to difference between treatment groups.
†Self reported incidence or when indicated as cause of death anywhere on death certificate from mortality
certification; ICD coding as in table 3.
‡Data collected at end of trial; excludes missing data. Self reported falls are a positive response to the
question, “Have you had any falls in the past 12 months?”
Table 5 Bone heel ultrasound attenuation, velocity of sound, and concentrations of serum vitamin D and parathyroid hormone in subgroup of participants
from general practice. Values are means (standard deviations) unless stated otherwise
Measurement
All Men Women
Vitamin D
(n=124)
Placebo
(n=114) P value
Vitamin D
(n=65)
Placebo
(n=57) P value
Vitamin D
(n=59)
Placebo
(n=57) P value
Age (years) 76.1 (5.1) 75.4 (4.1) 0.20 75.7 (5.1) 75.0 (3.6) 0.37 76.6 (5.1) 75.7 (4.5) 0.33
Body mass index (kg/m2) 27.4 (4.2) 26.6 (4.2) 0.15 26.9 (4.0) 26.2 (3.0) 0.30 28.0 (4.5) 27.1 (5.1) 0.28
Vitamin D (nmol/l) 74.3 (20.7) 53.4 (21.1) <0.001 75.6 (19.0) 61.0 (21.5) <0.001 72.0 (22.5) 45.37 (17.6) <0.001
Parathyroid hormone (pmol/l) 5.2 (2.0) 5.5 (2.4) 0.25 4.8 (2.0) 5.0 (2.0) 0.68 5.6 (1.9) 6.13 (2.6) 0.25
Bone heel ultrasound attenuation
(dB/MHz)
74.4 (21.9) 72.3 (19.7) 0.45 89.1 (15.4) 83.5 (16.2) 0.05 57.9 (15.4) 60.95 (16.3) 0.30
Velocity of sound (m/s) 1618.1 (41.2) 1613.6 (38.6) 0.39 1641.1 (32.2) 1629.2 (34.5) 0.05 1592.4 (34.5) 1597.7 (36.2) 0.42
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Generalisability
To maximise generalisability, this was a pragmatic trial
with minimal exclusion criteria. The doctors were simi›
lar to the general practice population in terms of com›
pliance, fracture rates, and effects of vitamin D. Blood
concentrations of vitamin D in participants taking pla›
cebo were comparable to those of population groups
of similar ages in northern latitudes in the United
States3 and higher than those in older European popu›
lations living in northern latitudes.16 20 If vitamin D
supplementation is safe and effective for fracture
prevention, even in relatively replete healthy partici›
pants, it is unlikely to be of lesser benefit in people with
lower vitamin D levels.
Public health implications
This trial was a pilot for a larger trial that was not
funded and was, consequently, too small for any
decisive effect on fractures to be expected. The results,
nevertheless, indicate that isolated vitamin D supple›
mentation prevents fractures. This is particularly
important for primary prevention. Several
interventions—such as bisphosphonates, oestrogen,
and calcium and vitamin D—reduce fractures in high
risk groups.2–7 Their application to primary prevention
is, however, problematic as the balance of risk›benefit
and cost›benefit differs in primary and secondary pre›
vention.
The alendronate trial identified 2000 women at
high risk of fracture (low bone mineral density and
previous fracture).4 The 25% reduction in fractures
seen translates to an absolute benefit of 60 women
treated for one year to prevent any fracture; the
absolute benefit was lower in a later trial on women
without a previous fracture.5 Whereas relative reduc›
tions in fracture may be generalisable, the absolute
benefit differs in groups in which absolute fracture
risks are lower. The 22% reduction in fractures in our
study translates to approximately 250 people treated
for one year to prevent any fracture.
Risk of fracture is related to bone health across the
whole population distribution, such that most fractures
do not occur in the small numbers of people with
severe osteoporosis at very high risk but in the large
numbers at moderately increased risk. To have a
substantial effect on total fractures in the population,
intervention would be needed in large numbers of
people; consequently, population›wide preventive
interventions have been proposed for all elderly
people.21
However, the dilemma for primary prevention is
that whereas the population attributable risk is large,
the absolute individual risk is still low.22 The risk›benefit
balance for community based prevention differs from
that for intervention in clinically defined groups.
Safety, feasibility, and cost effectiveness are crucial. Side
effects are less acceptable in a healthy group in which
the risk of fracture is not high. This is a particular issue
in men, in whom evidence on effective fracture preven›
tion is lacking. Many interventions effective in high risk
groups are not feasible in the general population
owing to poor compliance or side effects or are not
cost effective.23 In contrast, the cost of four monthly
oral 100 000 IU vitamin D is minimal ( < £1 annually).
Conclusion
We found a single oral 100 000 IU dose of vitamin D
four monthly to be acceptable, safe, and effective in
reducing the incidence of fracture in men and women
aged over 65 living in the general community.
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